Leerink Partnrs Issues Negative Forecast for OmniAb Earnings

OmniAb, Inc. (NASDAQ:OABI - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for OmniAb in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of ($0.64) for the year, down from their previous estimate of ($0.63). The consensus estimate for OmniAb's current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb's Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.61) EPS.

OmniAb (NASDAQ:OABI - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The business had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. During the same quarter last year, the business posted ($0.14) EPS.

A number of other research firms have also recently issued reports on OABI. Benchmark lowered their target price on OmniAb from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Thursday. HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of OmniAb in a report on Wednesday, March 19th.

Remove Ads

OmniAb Trading Down 3.2 %

Shares of NASDAQ OABI traded down $0.08 during mid-day trading on Friday, reaching $2.45. 374,019 shares of the company's stock were exchanged, compared to its average volume of 537,792. OmniAb has a twelve month low of $2.23 and a twelve month high of $5.63. The firm has a market capitalization of $345.98 million, a price-to-earnings ratio of -3.95 and a beta of -0.14. The business has a fifty day simple moving average of $3.34 and a 200 day simple moving average of $3.76.

Insiders Place Their Bets

In other OmniAb news, Director John L. Higgins bought 125,750 shares of OmniAb stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average price of $2.35 per share, for a total transaction of $295,512.50. Following the completion of the acquisition, the director now owns 2,762,887 shares of the company's stock, valued at $6,492,784.45. This trade represents a 4.77 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares in the company, valued at $1,111,935.60. The trade was a 6.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 112,260 shares of company stock valued at $376,601 in the last quarter. 8.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC raised its stake in shares of OmniAb by 33.3% during the 4th quarter. Squarepoint Ops LLC now owns 39,264 shares of the company's stock worth $139,000 after purchasing an additional 9,809 shares in the last quarter. Sherbrooke Park Advisers LLC increased its holdings in OmniAb by 53.5% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company's stock worth $61,000 after buying an additional 6,001 shares during the last quarter. ProShare Advisors LLC raised its position in OmniAb by 29.9% during the fourth quarter. ProShare Advisors LLC now owns 31,724 shares of the company's stock worth $112,000 after acquiring an additional 7,302 shares in the last quarter. Northeast Financial Consultants Inc acquired a new stake in OmniAb in the fourth quarter valued at $393,000. Finally, Millennium Management LLC lifted its stake in OmniAb by 49.7% in the fourth quarter. Millennium Management LLC now owns 186,745 shares of the company's stock valued at $661,000 after acquiring an additional 61,993 shares during the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.